Denise Bruner
Internal Medicine · Arlington, VANPI 1669517280
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $186,210 of the $227,435 with a category attached, or 81.9%. Novo Nordisk accounts for 99.9% of it on its own, with 3 other manufacturers making up the rest. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 225 payments — averaging $1010.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$227K
- Merz North America, Inc.$140
- AstraZeneca$47
- Currax Pharmaceuticals LLC$15
What the payments were for
- Speaking & faculty fees$186,21082%
- Travel & lodging$34,14115%
- Food & beverage$7,0523%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 220 | $227,233 |
| Merz North America, Inc. | 1 | $140 |
| AstraZeneca | 3 | $47 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$227,435 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 51 | $46,660 |
| OzempicSemaglutide | 15 | $35,851 |
| TrulicityDulaglutide | 12 | $16,841 |
| RybelsusSemaglutide | 12 | $11,030 |
| SynthroidLevothyroxine Sodium | 26 | $1,395 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,393 |
| Armour ThyroidThyroid,pork | 14 | $1,299 |
| Levothyroxine Sodium | 54 | $734 |
| Liothyronine Sodium | 13 | $627 |
| Np ThyroidThyroid,pork | 18 | $469 |
| Potassium Chloride | 19 | $464 |
| Zolpidem Tartrate | 25 | $463 |
| Rosuvastatin Calcium | 15 | $433 |
| ProgesteroneProgesterone, Micronized | 11 | $285 |
| Spironolactone | 12 | $273 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $227,233 | $46,88127 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.
Other internal medicine in Arlington
- Kumar AbhishekMechanicsville$1M
- Amit MahajanFalls Church$1M
- Kevin DonohueFalls Church$655K
- Anjali KaloreMidlothian$215K
- Scott GerrishVienna$207K
- Lawrence SchwartzRichmond$205K
- Wally SmithRichmond$177K
- Gautam GulatiMc Lean$136K
- Francesse BatailleDumfries$109K
- Brian WassermanNorth Chesterfield$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.